VistaGen Therapeutics
VTGN
33 hedge funds and large institutions have $1.82M invested in VistaGen Therapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 54 closing their positions.
11.76% more ownership
Funds ownership: 0.58% → 12.35% (+12%)
31% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 16
60% less funds holding
Funds holding: 83 → 33 (-50)
62% less capital invested
Capital invested by funds: $4.79M → $1.82M (-$2.97M)
93% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$548K |
| 2 |
Millennium Management
New York
|
+$354K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$207K |
| 4 |
Goldman Sachs
New York
|
+$189K |
| 5 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$167K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.17M |
| 2 |
State Street
Boston,
Massachusetts
|
-$662K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$202K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$179K |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$72.9K |
VTGN Hedge Fund Activity: Q2 2023 in Review
33 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2023, worth a combined $1.82M — down 62% from $4.79M a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of VTGN and 4 opened new positions — a net loss of 50 holders — while 16 trimmed existing stakes and 11 added.
The largest buyer was GSA Capital Partners, adding an estimated $548K. The largest seller was BlackRock, cutting an estimated $1.17M.
- 33 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2023, down from 83 in Q1 2023.
- Funds reported $1.82M of VistaGen Therapeutics stock for Q2 2023, down 62% quarter-over-quarter.
- 4 funds opened new VistaGen Therapeutics positions in Q2 2023 and 54 closed out, a net change of -50 holders.
- The largest VistaGen Therapeutics buyer in Q2 2023 was GSA Capital Partners, an estimated $548K added.
- The largest VistaGen Therapeutics seller in Q2 2023 was BlackRock, an estimated $1.17M sold.
Based on aggregated 13F filings for Q2 2023.